Clinical Outcomes of Holmium-166 Radioembolization with Personalized Dosimetry in Hepatocellular Carcinoma Treatment

Ziel/Aim: Holmium-166 transarterial radioembolization (TARE) has emerged as a potent locoregional treatment for hepatocellular carcinoma (HCC). The application of personalized dosimetry allows, compared with standard methods, a more precise planning and evaluation of radiation dose to the tumor while minimizing exposure to healthy liver tissue, which may improve clinical outcomes.

Methodik/Methods: This study analyzed 27 HCC patients who underwent 36 Ho-166 TARE treatments. Patients were treated using the Holmium platform, involving QuiremScout and QuiremSpheres microspheres for planning and treatment, respectively. Personalized dosimetry was performed using the Q-Suite software package to calculate target and non-target doses. Patients were followed up for at least 12 months post-treatment.

Ergebnisse/Results: At 3-month follow-up, disease control in the treated liver was achieved in 81.8% of patients, including complete remission in 36.4%, partial remission in 31.8%, and stable disease in 13.6%. The median progression-free survival (PFS) in the treated liver was 11 months. Overall survival (OS) after HCC diagnosis and after TARE were 25.6 and 17.2 months, respectively. A statistically significant correlation between radiation dose and clinical outcome was observed, with higher tumor doses positively correlating with prolonged PFS and OS.

Schlussfolgerungen/Conclusions: These results highlight the efficacy of personalized Ho-166 radioembolization in treating HCC and underscore the importance of precise dosimetry for optimizing therapeutic outcomes. Personalized dosimetry could enhance the accuracy of treatment planning and improve survival rates in HCC patients.

Publikationsverlauf

Artikel online veröffentlicht:
12. März 2025